Sadiya Bi Shaikh and Yashodhar Prabhakar Bhandary* Pages 1 - 14 ( 14 )
Respiratory diseases are one of the prime topics of concern in the current era due to improper diagnostics tools. Gene-editing therapy like Clustered regularly interspaced palindromic repeats-associated nuclease 9 (CRISPR/Cas9) is gaining popularity in pulmonary research opening up doors to invaluable insights on underlying mechanisms. CRISPR/Cas9 can be considered as a potential gene editing tool with a scientific community that is helping in the advancement of knowledge in respiratory health and therapy. As an appealing therapeutic tool, we hereby explore the advanced research on the application of CRISPR/Cas9 tool in chronic respiratory diseases such as lung cancer, Acute respiratory distress syndrome (ARDS), cystic fibrosis (CF). We also address the urgent need to establish this gene-editing tool in various other lung diseases such as asthma, Chronic obstructive pulmonary disease (COPD) and Idiopathic pulmonary fibrosis (IPF). The present review introduces CRISPR/Cas9 as a worthy application in targeting epithelial-mesenchymal transition and fibrinolytic system via editing specific genes. Thereby, based on the efficiency of CRISPR/Cas9, it can be considered as a promising therapeutic tool in respiratory health research.
CRISPR/Cas9, respiratory diseases, gene editing, gene therapy, lungs-related diseases, pulmonary disease.
Yenepoya Research Centre, Yenepoya (Deemed to be University), Deralakatte, Mangalore – 575 018, Karnataka, Yenepoya Research Centre, Yenepoya (Deemed to be University), Deralakatte, Mangalore – 575 018, Karnataka